Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Shares Sold by Sigma Planning Corp

Sigma Planning Corp lessened its stake in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) by 6.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 23,375 shares of the biotechnology company’s stock after selling 1,500 shares during the period. Sigma Planning Corp’s holdings in Rocket Pharmaceuticals were worth $294,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in RCKT. Wellington Management Group LLP grew its position in Rocket Pharmaceuticals by 22.8% in the 3rd quarter. Wellington Management Group LLP now owns 11,242,144 shares of the biotechnology company’s stock valued at $207,642,000 after acquiring an additional 2,086,424 shares in the last quarter. State Street Corp grew its holdings in shares of Rocket Pharmaceuticals by 11.6% in the third quarter. State Street Corp now owns 3,102,022 shares of the biotechnology company’s stock valued at $57,294,000 after purchasing an additional 322,156 shares in the last quarter. Maverick Capital Ltd. grew its holdings in shares of Rocket Pharmaceuticals by 4.8% in the third quarter. Maverick Capital Ltd. now owns 4,118,672 shares of the biotechnology company’s stock valued at $76,072,000 after purchasing an additional 190,360 shares in the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of Rocket Pharmaceuticals by 3.8% in the third quarter. Westfield Capital Management Co. LP now owns 4,493,833 shares of the biotechnology company’s stock valued at $83,001,000 after purchasing an additional 165,911 shares in the last quarter. Finally, Sovran Advisors LLC acquired a new position in shares of Rocket Pharmaceuticals in the fourth quarter valued at approximately $1,895,000. Institutional investors and hedge funds own 98.39% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Wedbush assumed coverage on shares of Rocket Pharmaceuticals in a research note on Monday, December 30th. They issued an “outperform” rating and a $32.00 price target for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $65.00 target price on shares of Rocket Pharmaceuticals in a research note on Tuesday, November 19th. Chardan Capital lowered their target price on Rocket Pharmaceuticals from $62.00 to $54.00 and set a “buy” rating for the company in a research note on Friday. Leerink Partners lowered their price objective on Rocket Pharmaceuticals from $46.00 to $44.00 and set an “outperform” rating for the company in a research report on Tuesday, November 19th. Finally, Jefferies Financial Group started coverage on Rocket Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $29.00 price objective for the company. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $45.64.

Rocket Pharmaceuticals Trading Up 0.5 %

Shares of Rocket Pharmaceuticals stock opened at $9.45 on Friday. The company has a fifty day simple moving average of $10.94 and a 200-day simple moving average of $14.78. Rocket Pharmaceuticals, Inc. has a 12-month low of $8.94 and a 12-month high of $31.24. The company has a current ratio of 6.05, a quick ratio of 6.05 and a debt-to-equity ratio of 0.06. The stock has a market cap of $861.43 million, a price-to-earnings ratio of -3.44 and a beta of 0.98.

Rocket Pharmaceuticals (NASDAQ:RCKT) last released its quarterly earnings data on Monday, March 3rd. The biotechnology company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.06. On average, equities analysts forecast that Rocket Pharmaceuticals, Inc. will post -2.83 EPS for the current fiscal year.

About Rocket Pharmaceuticals

Rocket Pharmaceuticals, Inc, together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia.